View Document Preview and Link Document Date: 2014-11-06 23:49:48 Open Document File Size: 226,68 KB Share Result on Facebook
Company AEs / Eastern Cooperative Oncology Group / Bayer Australia Pty Ltd / ITT / / Country Australia / / Currency USD / / IndustryTerm treatment of certain patients with prostate cancer / proposed clinical algorithm / treatment of castration-resistant prostate cancer / / MedicalCondition least two skeletal metastases / symptomatic bone metastases / disease / castration-resistant prostate cancer / thrombocytopenia / carcinoma / bone metastases / pain / painful bony metastases / skeletal metastases / experienced disease / refractory prostate cancer / visceral metastatic disease / prostate cancer / resistant prostate cancer / gastrointestinal disorders / / MedicalTreatment hormonal therapy / alternative therapies / chemotherapy / radiotherapy / hormone therapy / radiation / / Organization ADMINISTRATION OF STRONTIUM-89 / ADMINISTRATION OF Sm-LEXIDRONAM / Protocol Advisory SubCommittee / Therapeutic Goods Administration / Department of Health / ADMINISTRATION OF RADIUM-223 / Medicare / / Person Feedback Feedback / / Position Governor / Consumer/Consultant / nuclear medicine physician / / Product ketoconazole / Mitoxantrone / / Technology alpha / radiation / chemotherapy / radiopharmaceuticals / proposed clinical algorithm / / URL www.pbs.gov.au / / SocialTag 
MSAC Public Summary Document Application No. 1268 – Radium-223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases Sponsor/Applicant/s: